Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
36 results about "Serum iron tests" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Serum iron is a medical laboratory test that measures the amount of circulating iron that is bound to transferrin. Clinicians order this laboratory test when they are concerned about iron deficiency, which can cause anemia and other problems. 65% of the iron in the body is bound up in hemoglobin molecules in red blood cells.
Methods and compositions for regulating iron homeostasis by modulation of bmp-6
ActiveUS20100136015A1High in ironIncreased transferrin saturationOrganic active ingredientsAntibody mimetics/scaffoldsSerum iron testsAntibody
Modulation of iron homeostasis by regulating BMP-6 activity is provided. Methods of using BMP-6 and BMP-6 protein-specific reagents, such as antibodies, for altering serum iron levels in humans are provided. Such antibodies are useful in pharmaceutical compositions for the prevention and treatment of hemochromatosis and anemia of inflammation.
Owner:THE GENERAL HOSPITAL CORP
Methods and compositions for regulating iron homeostasis by modulation of BMP-6
ActiveUS8318167B2High in ironHigh saturationAntibody mimetics/scaffoldsImmunoglobulins against growth factorsPhysiologySerum iron tests
Owner:THE GENERAL HOSPITAL CORP
SiRNA and recombination lentivirus from preventing hepcidin from regulating protein and uses thereof
The invention discloses an RNA with little interference for inhibiting the expression of an iron regulating element regulatory protein (HJV). The RNA with little interference is in reverse complementation with the iron regulating element regulatory protein gene mRNA, and the length of the RNA is 19-27bp. The invention further discloses a DNA for coding the corresponding shRNA of the RNA with little interference and a recombined slow virus capable of expressing the shRNA. The RNA with little interference, the DNA capable of coding the shRNA and the recombined slow virus can effectively inhibit the expression of the iron regulating element regulatory protein in vivo, improve the level of the iron regulating element and reduce the level of serum iron in vivo, thereby reaching the aim of curing diseases related to iron metabolism.
Owner:THE HONG KONG POLYTECHNIC UNIV SHENZHEN RES INST
Methods and compositons for regulating iron homeostasis by modulation of bmp-6
InactiveUS20140086919A1High in ironHigh saturationImmunoglobulins against growth factorsAntibody ingredientsSerum igePhysiology
Modulation of iron homeostasis by regulating BMP-6 activity is provided. Methods of using BMP-6 and BMP-6 protein-specific reagents, such as antibodies, for altering serum iron levels in humans are provided. Such antibodies are useful in pharmaceutical compositions for the prevention and treatment of hemochromatosis and anemia of inflammation.
Owner:THE GENERAL HOSPITAL CORP
Methods and compositions for regulating iron homeostasis by modulation of bmp-6
InactiveUS20140199314A1High in ironHigh saturationAnimal cellsSugar derivativesAntiendomysial antibodiesPharmaceutical drug
Owner:THE GENERAL HOSPITAL CORP
Radiation biological dose estimation method based on serum iron/serum copper
InactiveCN103267972AAccurate estimateSave time estimatingDosimetersColor/spectral properties measurementsSerum ironDosimeter
The invention belongs to the field of radiation biological dose meters, and particularly relates to a characteristic project estimation technique using serum iron and serum copper as a marker. The technique includes the steps of measuring the concentration of the serum iron and the concentration of the serum copper of a radiated mouse respectively by using a 2-(5-bromine-2-pyridine azobenzene)-5-2-diethylaminophenol (5-Br-PADAP) spectrophotometric method, calculating the ratio of the serum iron and the serum copper, and then establishing a dose-response curve between the serum iron / serum copper and a radiation dose. According to the established dose-response curve, the dose response range of the biological dose estimation technique is 0.5-7Gy, operation and index analysis are convenient, information of the radiation dose can be acquired in 30 minutes, and the requirement for biological dose reconstruction can be met. Due to the fact that the technique has the advantages that the dose response is good, detection is convenient and mass detection can be carried out, the technique has broad application prospects in biological dose estimation for nuclear radiation accidents or professional radiated workers.
Owner:NANJING UNIV OF AERONAUTICS & ASTRONAUTICS
Compositions and their uses directed to hepcidin
InactiveUS20070275913A1Modulate expressionBiocideSugar derivativesErythropoiesis-stimulating agentTreated animal
Disclosed herein are compounds, compositions and methods for modulating the expression of hepcidin in a cell, tissue or animal or preventing, ameliorating or treating anemia. Also provided are methods for prevention, amelioration or treatment of anemia, and for increasing red blood cell count in an animal. Also provided are methods for the prevention, amelioration and / or treatment of low serum iron levels, low red blood cell count and other clinical endpoints of anemia in an animal. These methods may be achieved by administration of compounds or compositions including antisense compounds targeted to a nucleic acid that expresses hepcidin polypeptide combined with an erythropoiesis stimulating agent.
Owner:XENON PHARMACEUTICALS INC
Medicine application of iron liposome
InactiveCN101708184AIncreases available ironIncrease serum iron levelsHeavy metal active ingredientsBlood disorderFood additiveTreatment effect
The invention discloses a medicine application of iron liposome. By taking animals with chronic inflammation as a model, a brand-new medicine which treats anaemia caused by the dysfunction of the iron absorption of the small intestine to relevant protein molecules and takes the iron liposome as an effective component is provided. The invention takes white rats with inflammatory anaemia as a model, adopts an oral stomach infusion method and compares the curative effect of the iron liposome for the anaemia with that of a chalybeate which is not enveloped by the liposome, and the iron liposome can obviously enhance the levels of the hemoglobin, the blood cell volume, the serum iron and the saturation rate of the transferrin of an organism in a short time, can act as a very good curative effect to the inflammatory anaemia and can not cause injuries to the health of the organism. The iron liposome is obviously superior to the traditional iron-replenished preparation. The invention can be used for treating the anaemia caused by the dysfunction of the iron absorption of the small intestine to the protein molecules because of various known or unknown reasons. Various tablets, capsules, dripping pills, oral liquid and food additives which are taken orally and contain the iron liposome are prepared.
Owner:HEBEI NORMAL UNIV
Iron Supplement and Utilization of the Same
InactiveUS20080113899A1Increase of concentration of ironStrong tasteOrganic active ingredientsHeavy metal active ingredientsFood additiveSerum ige
The present inventors have found that a siderophore-iron (III) ion chelate complex is highly absorbed in the body; significantly increases the blood hemoglobin concentration, the serum iron concentration and the concentration of iron stored in the liver; and causes no adverse effects on the body. On the basis of these findings, the present inventors provide iron supplementing agents, agents for the prevention or treatment of iron defeciency anemia, food additives and food compositions, each of which contains a siderophore and iron (III) ions, preferably in the form of a chelate complex.
Owner:GEKKEIKAN SAKE CO LTD
Total iron binding force detection kit and preparation method thereof
The invention belongs to the technical field of biology and belongs to a total iron binding force detection kit, in particular, a preparation method of a total iron binding force detection kit. The preparation method involves the preparation of a reagent R1 and the preparation of a reagent R2; a solution preparation tank is arranged on a magnetic stirrer; a solution is made to keep a medium-speedrotating state; a Tris buffer solution, ferrous azine, ascorbic acid and a second buffer solution are added when stirring is performed; stirring is performed for 30 minutes until the materials are completely dissolved, and the solution is clear and transparent and has no precipitate at the bottom of the solution preparation tank; and volume fixing is carried out, so that the volume of the solutioncan be a final volume. According to the detection kit, a spectrophotometric method is adopted to detect a total iron binding force with the ferrous azine used as a substrate; serum iron combined withtransferring, in an acidic medium, is dissociated from the transferrin; and the serum iron is reduced into Fe <2+> by a reducing agent, the Fe <2+> and the ferrous azine generate a purplish red compound; a absorbance value at 562nm is detected by a spectrophotometer, so that total iron content in serum and plasma samples can be detected; and the linear range of the kit can reach 50-400 micromole / L.
Owner:苏州普瑞斯生物科技有限公司
Application of hydrogen sulfide in preparing medicines for treating inflammatory anemia
The invention belongs to the fields of medicines and pharmacology, and relates to a novel pharmaceutical application of hydrogen sulfide in pharmacology, in particular to an application of the hydrogen sulfide in preparing medicines for treating inflammatory anemia. By conducting experiments on the influence of the hydrogen sulfide on the serum iron of normal mice and mice with the inflammatory anemia, experimental results indicate that the hydrogen sulfide, under a physiological condition, can significantly improve the serum iron and iron-carrying saturation of the mice by increasing TFR (transferrin receptor) protein expression; for a model of the mice with the inflammatory anemia, the hydrogen sulfide, by inhibiting the decrease of TFR and EPN proteins caused by lipopolysaccharide, can significantly inhibit the decline of the serum iron and iron-carrying saturation caused by the lipopolysaccharide; and for peritoneal induced primary macrophage, the hydrogen sulfide, under the physiological condition, can significantly increase the TFR protein expression, and for a lipopolysaccharide-processed cell mode, the hydrogen sulfide can inhibit lipopolysaccharide-induced TFR decrease. The experimental results prove that the hydrogen sulfide can be used for preparing the medicines for treating the inflammatory anemia.
Owner:FUDAN UNIV
Thiazolidone compound and application of thiazolidone compound in preparation of medicine used for treating iron disorder-related diseases
ActiveCN104370852ALower iron levelsOrganic active ingredientsOrganic chemistryChemical structureSerum iron
The invention discloses a thiazolidone compound, wherein a chemical structure of the thiazolidone compound is shown in a general form (I). The invention also discloses application of the thiazolidone compound in preparation of a medicine used for treating thalassemia. Experiments prove that the thiazolidone compound can be used for effectively stimulating expression of hepcidin in cells under the condition that concentration is 10mu M, can be still used for effectively inducing expression of hepcidin in liver when being exposed for 6 hours, 24 hours and 48 hours respectively at a dosage of 30mg / kg in animal level and can be also used for effectively reducing level of serum iron, so that the thiazolidone compound can take hepcidin as a target, can be used for reducing iron level in serum, is hopeful to be a potential medicine used for treating and alleviating iron disorder-related diseases and has a broad clinical application prospect and a great economic development value.
Owner:SHANDONG UNIV
Application of iron removal drug to preparation of H7N9 type bird flu prevention and treatment drugs
InactiveCN109045000ALower serum iron levelsHelp fight infectionAntiviralsAmide active ingredientsBird fluSerum iron
The invention relates to the field of medical science. By detecting the serum iron content in the body of an H7N9 type bird flu patient, it is discovered that decreasing of the serum iron plays the important role in engine body resisting H7N9 bird flu infection, and application of the iron removal drug to preparation of the H7N9 type bird flu prevention and treatment drugs is disclosed through experimental data, theoretical support is provided for prevention and treatment of H7N9 bird flu virus, and particularly basis is provided for research and development of drugs for preventing and treating H7N9 bird flue virus.
Owner:ZHEJIANG UNIV
Therapeutic effect of ghrelin and L-serine compound on sepsis
PendingCN111514281AGood treatment effectRelieve encephalopathyAntibacterial agentsOrganic active ingredientsTherapeutic effectCecal ligation
The invention discloses therapeutic effect of a ghrelin and L-serine compound on sepsis. Experiments are carried out from an in-vivo level and an in-vitro level. An in-vivo animal model experiment adopts a cecum ligation puncture mouse sepsis model CLP. An in-vitro experiment adopts primary cells corresponding to the small intestine, the liver and the spleen of a mouse. The expression change of iron metabolism related protein in each tissue / cell of a false operation group, a cecum ligation puncture group and a condition of cecum ligation puncture with exogenous ghrelin is observed, the expression of the iron metabolism related protein and the change of cell iron content are observed after the a GHSR1a receptor and MAPK (ErK1 / 2) signal paths are activated or blocked, changes of serum iron content, erythrocyte generation and tissue iron content of the mouse are monitored, and it is verified that the ghrelin / GHSR1a / MAPK participates in regulation and control of iron mobilization among tissues of a body under a cecum ligation perforation model, increases serum iron, reduces hepcidin, promotes hemoglobin synthesis, and finally relieves sepsis anemia and tissue hypoxia injury.
Owner:AFFILIATED HOSPITAL OF NANTONG UNIV
Compositions and methods for increasing iron intake in a mammal
ActiveUS20190054115A1Improve bioavailabilityDose lessHeavy metal active ingredientsDispersion deliveryBioavailabilityBuffering agent
Compositions containing iron, buffering agent and denatured protein have been prepared that are capable of increasing serum iron in a subject. For example, spray dried microbeads have been prepared containing iron entrapped within a protein matrix and unbound iron in a buffered composition that provides a gastroprotective effect, preserves iron in the more available Fe2+ form and improves iron bioavailability in humans relative to previously known vehicles for delivering iron to a subject.
Owner:SOLVOTRIN THERAPEUTICS LTD
Serum iron determination kit and preparation method and application thereof
ActiveCN109613280ANo reconstitution requiredPromote decompositionBiological testingSerum ironThiourea
The invention discloses a serum iron determination kit. The kit comprises a reagent R1 and a reagent R2. The reagent R1 comprises a buffer solution, ascorbic acid, a de-interfering agent, a stabilizer, a surfactant, and a preservative. The reagent R2 comprises a buffer solution and bathophenanthroline disulfonic acid disodium salt. The invention further relates to a preparation method and application of the serum iron determination kit. The stable serum iron is a liquid double-reagent, reconstitution preparation is not required, and therefore the stable serum iron can be directly used when taken out from a bottle. The stabilizer is added in the reagent R1 to facilitate stability and reducibility maintenance of the ascorbic acid. The de-interfering agent is added in the reagent R1, thioureais mixed with a ascorbic acid solution, and therefore the R1 can be adopted as a masking agent as well as a reducing agent, and interference from other ions can be avoided. The reagent has high sensitivity. The kit is convenient to use, is high in specificity, is high in accuracy, is free of pollution to biochemical instruments, and can be further popularized in the market.
Owner:中拓生物有限公司
A stable serum iron detection kit
ActiveCN106814063BImprove stabilityAccuracy impactMaterial analysis by observing effect on chemical indicatorColor/spectral properties measurementsSerum igeSerum iron
The invention discloses a serum iron ferrous pyrazine colorimetric detection kit, and belongs to the technical field of clinical in vitro detection reagents. The kit is prepared from a reagent R1 and a reagent R2. Buffer solutions of the reagent R1 and the reagent R2 are replaced as 60mM of Tris buffer solution with pH of 4.2, and then a surfactant of the reagent R1 is replaced as TrixtonX-100. The stability of the kit is improved, the linear dependence is better, the accuracy of the reagents are good, and the further popularization and use in the market are benefited.
Owner:BIOBASE BIODUSTRY (SHANDONG) CO LTD
Compositions and their uses directed to hepcidin
Disclosed herein are compounds, compositions and methods for modulating the expression of hepcidin in a cell, tissue or animal or preventing, ameliorating or treating anemia. Also provided are methods for prevention, amelioration or treatment of anemia, and for increasing red blood cell count in an animal. Also provided are methods for the prevention, amelioration and / or treatment of low serum iron levels, low red blood cell count and other clinical endpoints of anemia in an animal. These methods may be achieved by administration of compounds or compositions including antisense compounds targeted to a nucleic acid that expresses hepcidin polypeptide combined with an erythropoiesis stimulating agent.
Owner:XENON PHARMACEUTICALS INC
Application of iron removal drug in preparation of H7N9 bird flue preventive drugs
InactiveCN109464431ALower serum iron levelsHelp fight infectionAntiviralsAmide active ingredientsSerum ironIron removal
The invention relates to the medicine of biological medicine, and relates to application of an iron removal drug in the preparation of H7N9 bird flue preventive drugs. The invention discloses application of the iron removal drug in the preparation of H7N9 bird flue preventive drugs. The iron removal drug is deferoxamine; the deferoxamine can be used for preventing and / or curing H7N9 bird flue, that is, the content of serum iron for a patient is reduced by the deferoxamine, so that the effect of preventing H7N9 bird flue is reached.
Owner:ZHEJIANG UNIV
A thiazolidinone compound and its application in the preparation of medicines for treating diseases related to iron disorders
ActiveCN104370852BLower iron levelsOrganic active ingredientsOrganic chemistryChemical structureDisease
Owner:SHANDONG UNIV
Non-invasive and minimally-invasive detection of serum iron in real time
A non-invasive and minimally-invasive system and method of detecting iron content in nail and hair samples to diagnose iron deficiency anemia. The system comprises a portable and ultra sensitive magnetometer. A sample of hair or nail is collected from the patient and placed in the magnetometer. The magnetometer is sufficiently sensitive to detect or otherwise indicate the iron content of the sample. Diagnosis can be made based on the detected iron level.
Owner:3DT HLDG
Non-invasive and minimally-invasive detection of serum iron in real time
InactiveUS20200003755A1Low iron contentDiagnostic recording/measuringSensorsSerum ironLamina epithelialis
Non-invasive and minimally-invasive detection of serum iron in real time. In a method for detecting serum iron content disclosed herein, the method includes positioning a device relative to a nonpigmented epithelial layer covering capillaries of a mammalian subject, operating the device to obtain optical data relating to the capillaries, and determining serum iron content of blood within the capillaries based upon the optical data.
Owner:3DT HLDG
Methods and compositions for regulating iron homeostasis by modulation of bmp-6
InactiveUS20170362311A1High in ironHigh saturationAntibody mimetics/scaffoldsImmunoglobulins against growth factorsPhysiologySerum iron tests
Modulation of iron homeostasis by regulating BMP-6 activity is provided. Methods of using BMP-6 and BMP-6 protein-specific reagents, such as antibodies, for altering serum iron levels in humans are provided. Such antibodies are useful in pharmaceutical compositions for the prevention and treatment of hemochromatosis and anemia of inflammation.
Owner:THE GENERAL HOSPITAL CORP
Serum protein marker for tuberculosis drug resistance diagnosis and application thereof
The invention discloses an application of a serum protein marker as a tuberculosis drug resistance diagnosis marker. The serum protein is at least one of a complement protein C4A (C4A), a complement protein C4B (C4B), lactic dehydrogenase B (LDHB), keratinose 9 (KRT9), alpha-2 macroglobulin (A2M), a blood coagulation factor XI (F11), serum iron transferrin (TF), immune globulin alpha-1 (IGHA1), immune globulin (IGHM), immune globulin J chain (JCHAIN), V1-47 proteins (IGLV1-47) and V4-31 proteins (IGHV4-31). According to the application, analysis is carried out according to serum proteins of individuals of different tuberculosis drug resistance types, and a new thought is provided for the targeted therapy of the tuberculosis drug resistance from the angle of the serum proteins.
Owner:佛山市第四人民医院 +1
Kit for detecting ultra-early Parkinson's disease
PendingCN111537738AIncreased sensitivityImprove featuresDisease diagnosisBiological testingSerum ironAIDS diagnosis
The invention discloses a kit for detecting ultra-early Parkinson's disease, and belongs to the technical field of biological detection. The kit comprises an alpha-synuclein detection unit, a serum iron detection unit, a serum zinc detection unit, a GSH detection unit, a GSH-Px detection unit and an SOD detection unit. According to the kit, serum alpha-synuclein, metal ions Fe and Zn and GSH, GSH-Px and SOD are detected, related indexes of PD are comprehensively and jointly detected, the kit can be effectively used for auxiliary diagnosis of the ultra-early Parkinson's disease, and the sensitivity and specificity of auxiliary diagnosis are improved. Meanwhile, a required sample is blood, and compared with cerebrospinal fluid extraction and detection, the kit is more convenient and simplerand is more beneficial to clinical popularization.
Owner:AFFILIATED HOSPITAL OF NANTONG UNIV +1
Pharmaceutical preparation used for iron-deficiency anemia and preparation method thereof
InactiveCN107441245ASimple processEasy to operateAlgae medical ingredientsFungi medical ingredientsSerum ironMedicine
The invention belongs to the technical field of pharmaceutical extraction and discloses a preparation method of a pharmaceutical preparation used for iron-deficiency anemia. The preparation method comprises the following steps: 1) preparing a porphyra extract; 2) preparing agaric extracting solution; 3) preparing a fructus lycii extract; 4) preparing a Chinese date extract; 5) preparing peanut skin extracting solution; and 6) boiling, filtering, subpackaging and sterilizing. The pharmaceutical preparation can obviously improve contents of red blood cells, hemoglobin and serum iron, has the effect obviously better than that of the prior art and can be further applied to clinical experimental study.
Owner:XIANGYU PHARMA
Traditional Chinese medicine composition for preventing and treating thalassemia
PendingCN114073729ASignificant relief/treatment effectNo side effectsUnknown materialsBlood disorderDiseaseBeta thalassemia
The invention discloses an application of a traditional Chinese medicine composition in preparation of a medicine for relieving / treating thalassemia. The traditional Chinese medicine composition comprises angelica sinensis, astragalus membranaceus, colla corii asini, leonurus japonicus and pericarpium citri reticulatae. The composition can improve the hematological phenotype of beta thalassemia mice, increase the number of red blood cells, the content of hemoglobin and hematocrit, and reduce the content of serum iron and liver iron; the traditional Chinese medicine composition disclosed by the invention has an obvious relieving / treating effect on the thalassemia, not only widens the adaptation disease range of the components, but also provides a new traditional Chinese medicine formula choice for relieving / treating the thalassemia, and has an obvious application value for relieving / treating the thalassemia.
Owner:ZHUZHOU QIANJIN PHARMA
Methods and compositions for regulating iron homeostasis by modulation of bmp-6
InactiveUS20210388069A1High in ironIncreased transferrin saturationPeptide/protein ingredientsAntibody mimetics/scaffoldsAntiendomysial antibodiesPharmaceutical drug
Modulation of iron homeostasis by regulating BMP-6 activity is provided. Methods of using BMP-6 and BMP-6 protein-specific reagents, such as antibodies, for altering serum iron levels in humans are provided. Such antibodies are useful in pharmaceutical compositions for the prevention and treatment of hemochromatosis and anemia of inflammation.
Owner:THE GENERAL HOSPITAL CORP
Medicine application of iron liposome
InactiveCN101708184BIncreases available ironIncrease serum iron levelsHeavy metal active ingredientsBlood disorderFood additiveSerum iron
Owner:HEBEI NORMAL UNIV
Popular searches
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com